Comparison · NCT01489813-8aef41a5
Sugar Pill vs Genistein Supplement: Number of Participants With Cancer Recurrence Determined at 10-week Biopsy.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sugar Pill vs Genistein Supplement: Number of Participants With Cancer Recurrence Determined at 10-week Biopsy. Trial comparisons, record NCT01489813-8aef41a5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01489813-8aef41a5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.5 | 0.268 | 0.732 | wilson | |
| Risk in group 2 | 0.556 | 0.337 | 0.754 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0556 | -0.361 | 0.263 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.9 | 0.462 | 1.75 | log | |
| Odds ratio, group 1 over group 2 | 0.8 | 0.197 | 3.25 | log | |
| Number needed to treat, for one fewer participant with the outcome on Sugar Pill than on Genistein Supplement | 18 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sugar Pill | Patients will be given placebo pills for 10 weeks.~Sugar pill: Sugar pills will be taken by mouth three times daily (PO TID). | 7 | 14 | OG000 |
| Group 2 | Genistein Supplement | 30 mg of genistein supplement by mouth three times daily (PO TID) for 10 weeks.~Genistein: 30 mg of genistein supplement by mouth three times daily (PO TID). | 10 | 18 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Cancer Recurrence Determined at 10-week Biopsy.
- Description
- A secondary study endpoint will be the presence of cancer and the rate of recurrence as determined by the 10-week biopsy or subsequent standard follow-up visits.
- Time frame
- At 10 weeks of treatment.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
- NCT number
- NCT01489813
- Phases
- PHASE2
- Conditions
- Bladder Cancer
- Interventions
- Genistein, Sugar pill
- Lead sponsor
- Emory University
- Results first posted
- 2024-07-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01489813?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01489813-8aef41a5